BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial

Extensive Validation of BioMark's Comprehensive Metabolic Panel in German 10,000-Participant HANSE Study, within the context of an international consortium supported under the EUREKA Network.

Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the company has been invited to participate in the landmark HANSE lung cancer screening trial in Germany. This strategic clinical collaboration with Prof. Dr. Jens Vogel-Claussen at Medizinische Hochschule Hannover, Prof. Dr. Martin Reck at LungenClinic Grosshansdorf, and Dr. Sabine Bohnet at Universitätsklinikum Schleswig-Holstein, positions BioMark as the core diagnostic partner for German largest and most comprehensive screening study. The trial is designed to encompass 10,000 participants from both high-risk and general population cohorts, providing critical international market validation for BioMark's platform.

The consortium focuses on developing and implementing metabolomic profiling, radiomic, and clinical data into a risk-based model to improve the accuracy of early lung cancer detection and distinguish benign from malignant nodules. BioMark has been collaborating intensively with the German clinical team to finalize work packages and critical logistics for sample handling and processing as the trial started this October. This major initiative, which is supported through the international EUREKA Network Program, leverages BioMark's advanced Quebec City laboratory facilities, which are progressing toward full certification and accreditation to meet the stringent requirements of this large-scale European clinical trial.

"This collaboration represents a transformative milestone for BioMark," said Rashid Ahmed Bux, CEO and President of BioMark Diagnostics. "Our recent successful capital raise has allowed us to scale our laboratory operations to effectively manage this prestigious trial. We are honored to partner with Dr. Vogel-Claussen and his exceptional team. Their scientific rigor validates our liquid biopsy technology on the international stage and establishes a strong pathway to European market commercialization."